From bench to bedside: the history and progress of CAR T cell therapy

A Mitra, A Barua, L Huang, S Ganguly, Q Feng… - Frontiers in …, 2023 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of …

O Penack, M Marchetti, T Ruutu, M Aljurf… - The Lancet …, 2020 - thelancet.com
Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity
after allogeneic stem-cell transplantation. Because of the small number of results from well …

One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors

D Niederwieser, H Baldomero, N Bazuaye… - …, 2021 - pmc.ncbi.nlm.nih.gov
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission
of promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities …

Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

BL Scott, MC Pasquini, BR Logan, J Wu… - Journal of Clinical …, 2017 - ascopubs.org
Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation
(HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with …

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

B Gyurkocza, BM Sandmaier - Blood, The Journal of the …, 2014 - ashpublications.org
An essential component of allogeneic and autologous hematopoietic cell transplantation
(HCT) is the conditioning regimen administered before the hematopoietic cell infusion. Early …

Hematopoietic stem cell transplantation for patients with AML in first complete remission

JJ Cornelissen, D Blaise - Blood, The Journal of the American …, 2016 - ashpublications.org
Postremission therapy in patients with acute myeloid leukemia (AML) may consist of
continuing chemotherapy or transplantation using either autologous or allogeneic stem …

Adoptive cellular therapy: a race to the finish line

CH June, SR Riddell, TN Schumacher - Science translational medicine, 2015 - science.org
Adoptive T cell transfer for cancer, chronic infection, and autoimmunity is an emerging field
that shows promise in recent trials. Using the principles of synthetic biology, advances in cell …

Oral complications of cancer and cancer therapy: from cancer treatment to survivorship

JB Epstein, J Thariat, RJ Bensadoun… - CA: a cancer journal …, 2012 - Wiley Online Library
Answer questions and earn CME/CNE Oral complications resulting from cancer and cancer
therapies cause acute and late toxicities that may be underreported, underrecognized, and …

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

L Muffly, MC Pasquini, M Martens… - Blood, The Journal …, 2017 - ashpublications.org
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell
transplantation (HCT) in adults≥ 70 years with hematologic malignancies across the United …

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

ML Sorror, MB Maris, R Storb, F Baron, BM Sandmaier… - Blood, 2005 - ashpublications.org
We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting
outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT) …